Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

作者：David Jones, Pol Boudes, Mark G. Swain, Christopher L. Bowlus, Michael Galambos, Bruce R. Bacon, Yvonne Döerffel, Norman Gitlin, Stuart C. Gordon, Joseph A. Odin, David Sheridan, M A Wörns, Virginia Clark, Linsey Corless, Heinz Hartmann, Mark Jonas, Andreas E. Kremer, George Mells, Peter Buggisch, B. Freilich, Cynthia Levy, John M. Vierling, David Bernstein, Marek Hartleb, Ewa Janczewska, Fedja A. Rochling, Hemant Shah, Mitchell L. Shiffman, John H. Smith, Yun‐Jung Choi, Alexandra Steinberg, Mónika Varga, Harinder Chera, Robert L. Martin, Charles A. McWherter, Gideon M. Hirschfield · 发表于：˜The œLancet. Gastroenterology & hepatology · 年份：2017 · DOI：10.1016/s2468-1253(17)30246-7 · 被引用次数：187 · 研究领域：Liver Diseases and Immunity、Drug Transport and Resistance Mechanisms、Pediatric Hepatobiliary Diseases and Treatments